What the research found

A large trial testing ziltivekimab—a drug designed to block interleukin-6 (IL-6), a circulating inflammatory marker—successfully lowered both IL-6 and high-sensitivity C-reactive protein (hs-CRP) in participants with atherosclerotic disease and chronic kidney disease. Despite this biochemical improvement, the drug failed to reduce heart attacks, strokes, or cardiovascular death. This mirrors an earlier setback with drugs targeting Lp(a), another blood biomarker long assumed to reflect coronary risk.

The underlying issue appears to be a mismatch between what blood biomarkers represent and what actually drives heart attacks. While elevated hs-CRP and IL-6 correlate with increased cardiovascular risk, they may reflect systemic inflammation elsewhere in the body—joint inflammation, infection, or other sources—rather than inflammation within the coronary arteries themselves. Recent imaging work using artificial intelligence to assess coronary inflammation directly (FAI scores) shows that blood biomarkers don't reliably predict arterial wall inflammation. A coronary artery can appear unobstructed on angiography yet show high inflammatory activity on imaging, or vice versa.

Why it matters for you

If you're tracking hs-CRP or other inflammatory biomarkers as proxies for cardiovascular health, the ZEUS trial is a reminder that their value is limited. A low hs-CRP doesn't guarantee your coronary arteries are quiet, and aggressively lowering it pharmacologically may not protect your heart. This doesn't mean inflammation is irrelevant—decades of pathology work confirm it drives plaque rupture and heart attacks—but the signal is being lost in translation.

For MyKine users, this reinforces the importance of multimodal assessment. Track hs-CRP if you like, but complement it with other markers of metabolic health (lipids, glucose stability, Lp(a) if you have family history), ensure your training and sleep protocols are solid (both reduce systemic inflammation), and don't assume a single biomarker tells the whole story. If you have atherosclerotic disease or significant risk factors, consider whether coronary imaging—not just blood work—is warranted, especially since silent atherosclerosis is common even in young adults.

Caveats

• The ZEUS trial results are unpublished; full data and methodology remain unavailable
• The inclusion criteria (chronic kidney disease + elevated baseline hs-CRP) may not generalise to all populations
• The trial targeted a specific pathway (IL-6); failure doesn't rule out benefit from other anti-inflammatory approaches (e.g. colchicine showed modest benefit in prior trials)
• Direct coronary inflammation imaging (FAI) is still research-grade and not yet standard clinical practice; correlation with long-term outcomes is ongoing
• The role of inflammation in heart attacks is established, but this trial shows blood biomarkers are imperfect surrogates for it